Population Analysis of Weight-, Age-, and Sex-Related Differences in the Pharmacokinetics of Lopinavir in Children from Birth to 18 Years
- 1 November 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (11) , 3548-3555
- https://doi.org/10.1128/aac.00943-05
Abstract
The pharmacokinetics of lopinavir were investigated by the use of a population approach performed with the nonlinear mixed effect modeling program NONMEM and 157 children ranging in age from 3 days to 18 years. The pharmacokinetics of lopinavir were well described by a one-compartment model in which the absorption and the elimination rate constants were equal. Typical population estimates of the apparent volume of distribution ( V / F ) and plasma clearance (CL/ F ) were 24.6 liters and 2.58 liters/h, respectively. The lopinavir V / F and CL/ F were both related to body weight (BW), with an important increase in weight-normalized CL/ F for the lowest BW. Combined treatment with lopinavir and nevirapine was found to increase the CL/ F . The lopinavir CL/ F was also age and sex related, as a 39% increase was observed after the age of 12 years for boys compared to the CL/ F for girls. The consequences of these pharmacokinetic discrepancies and the necessity to modify the currently recommended dosage regimen should be further investigated.Keywords
This publication has 30 references indexed in Scilit:
- Population pharmacokinetics of lopinavir in combination with ritonavir in HIV‐1‐infected patientsBritish Journal of Clinical Pharmacology, 2005
- Pharmacokinetics of Local Anaesthetics in Infants and ChildrenClinical Pharmacokinetics, 2004
- Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and ChildrenNew England Journal of Medicine, 2003
- Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenThe Pediatric Infectious Disease Journal, 2003
- The Influence of Sex on PharmacokineticsClinical Pharmacokinetics, 2003
- Changes in plasma protein binding have little clinical relevanceClinical Pharmacology & Therapeutics, 2002
- Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infectionClinical Pharmacology & Therapeutics, 2002
- Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infectionThe Pediatric Infectious Disease Journal, 2001
- Pharmacokinetics of the Protease Inhibitor Indinavir in Human Immunodeficiency Virus Type 1-Infected ChildrenAntimicrobial Agents and Chemotherapy, 2001
- Indinavir Pharmacokinetics and Parmacodynamics in Children with Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2000